Gaston Habets

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations

Medicine, Oncology, Pharmacology +14

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

James Tsai, John Tayu Lee, Weiru Wang et al. · Proceedings of the National Academy of Sciences · 2008 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +15

<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Fei Su, Amaya Virós, Carla Milagre et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

Medicine, Dermatology, Oncology +13

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

Elizabeth E. Spangenberg, Paul Severson, Lindsay A. Hohsfield et al. · Nature Communications · 2019 · 998 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

William D. Tap, Zev A. Wainberg, Stephen P. Anthony et al. · New England Journal of Medicine · 2015 · 582 citations

Medicine, Oncology, Pharmacology +15